Pharmacy Times
JULY 31, 2024
Pharmacies can adapt by embracing digital self-service options to better engage with patients, meet increasing consumer demand, and enhance revenue streams.
Drug Topics
JULY 30, 2024
CVS Caremark and the State of Illinois settled a lawsuit due to the company’s failure to pay contracted rebates.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Is Right For Me
JULY 23, 2024
Hey there, future pharmacists! I’m Shelby, a student pharmacist at the University of Findlay (UF), and I’m here to share my journey with you. If you’re thinking about a career in pharmacy or just curious about what it’s like, you’re in the right place! Falling in Love with Findlay My adventure started the summer before my senior year of high school at Findlay’s Summer Pharmacy Camp.
STAT
JULY 31, 2024
Mount Sinai, a leading hospital network in New York City, has mounted an extraordinary behind-the-scenes campaign to blunt the fallout over revelations about its controversial research project in which brain biopsies are taken from patients undergoing deep brain stimulation, STAT has learned. That has included not only enlisting its own patients to defend the research but also seeking to stop a professional society of neurosurgeons from issuing a statement that could have jeopardized the researc
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
JULY 25, 2024
Humana inked a new multi-year agreement with Google Cloud to modernize its cloud infrastructure and build out generative AI solutions. | Humana inked a new multi-year agreement with Google Cloud to modernize its cloud infrastructure and build out generative AI solutions.
Pharmaceutical Technology
JULY 22, 2024
As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
JULY 18, 2024
House Bill (HB) 1993 seeks to increase PBM transparency and accountability in an effort to combat the rising cost of prescription drugs.
Fierce Pharma
JULY 15, 2024
While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note f | While patent cliffs loom for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a July 11 research note from Morgan Stanley.
STAT
JULY 31, 2024
Untreated vision loss and high LDL cholesterol have been added as two new potentially modifiable risk factors for dementia in a report released Wednesday by the Lancet Commission. These new additions join 12 other risk factors outlined by the commission, affiliated with University College London, in previous reports on dementia prevention, intervention, and care in 2017 and 2020.
Fierce Healthcare
JULY 18, 2024
The sprawling enterprise that is UnitedHealth Group is undergoing more layoffs under its Optum umbrella. | UnitedHealth's Optum is again laying off workers, with the scope unconfirmed. Landmark Health is downsizing once again and leaving major metropolitan areas.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
BioPharm
JULY 24, 2024
GSK’s submission is supported by Phase III trials showing significant progression-free survival benefit and positive overall survival trends using Blenrep combinations compared to standard care.
Pharmacy Times
JULY 18, 2024
A large portion of the population of patients in the United States with GERD have the non-erosive type of the disease.
Drug Topics
JULY 18, 2024
Mayank Amin, PharmD, RPh, MBA, sat down with Drug Topics on part 1 of an episode of Over the Counter to share his experiences transforming a shuttered independent pharmacy into a thriving community hub.
Fierce Pharma
JULY 2, 2024
After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy—and a competitor to Eisai and Bioge | After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy, a competitor to Eisai and Biogen’s Leqembi, a full approval.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
JULY 29, 2024
Bird flu snapshot: This is the latest installment in a series of regular updates on the H5N1 flu outbreak in dairy cows that STAT is publishing on Monday mornings. To read future updates, you can also subscribe to STAT’s Morning Rounds newsletter. A network of nascent vaccine manufacturers in low- and middle-income countries will soon start preliminary work to develop messenger RNA vaccines targeting the H5N1 bird flu virus, an effort that could speed production during a pandemic, should
Fierce Healthcare
JULY 19, 2024
A widespread outage to Microsoft systems has impacted health systems, hospitals and clinics as electronic health record software has been knocked offline, forcing providers to cancel non-emergency | A widespread outage to Microsoft systems has impacted health systems, hospitals and clinics as electronic health record software has been knocked offline, forcing providers to cancel non-emergency procedures and services.
pharmaphorum
JULY 11, 2024
The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the prices of medicines in the US.
Pharmacy Times
JULY 11, 2024
In a follow-up to the interim FTC report documenting the business practices of PBMs and the power they hold in the pharmaceutical industry, the Commission now seeks to sue the 3 largest PBMs in the country for driving up the price of insulin and other essential drugs.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
JULY 23, 2024
A survey conducted by Surescripts, a health care solutions company, explored the attitudes of pharmacists and prescribers towards ongoing issues and challenges currently facing the industry.
Fierce Pharma
JULY 15, 2024
It's no secret that cell and gene therapies have faced manufacturing hurdles as the advanced medicines have become increasingly popular in recent years. | It's no secret that cell and gene therapies have faced manufacturing hurdles as the advanced medicines have become increasingly popular in recent years. Now, the FDA is proposing to work directly with industry through a series of facility tours that could enable both sides to learn something from each other.
STAT
JULY 29, 2024
The Food and Drug Administration on Monday approved a blood test intended to detect colon cancer, a product many experts hope will help catch cases of the disease early enough so that they can be more easily treated. The test, called Shield and made by Guardant Health, a Palo Alto, Calif.-based biotech firm, comes with a drawback: It is not as good as a colonoscopy and other tests at detecting precancerous or early stage cancers.
Fierce Healthcare
JULY 8, 2024
U.S. digital health startups pulled in $5.7 billion across 266 deals in the first six months of 2024, marking continued momentum in the sector after a rocky few quarters last year. | U.S. digital health startups pulled in $5.7 billion across 266 deals in the first six months of 2024, marking continued momentum in the sector after a rocky few quarters last year.
pharmaphorum
JULY 4, 2024
Changing Faces explores the digital and supplier hires from April 2024, with a focus on companies like SPT Labtech, Sphere Fluidics, Newel Health, and Diaceutics. Stay updated on the latest developments in the industry.
Pharmacy Times
JULY 2, 2024
Artificial intelligence (AI) may optimize cash pricing strategies in community pharmacies.
Drug Topics
JULY 15, 2024
Updated vaccines are expected to be available in the coming months.
Fierce Pharma
JULY 18, 2024
Pfizer’s blockbuster drug tafamidis for the treatment of the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) needs at least a 96% discount off its list price to be considered cost | Pfizer’s blockbuster tafamidis for the treatment of the rare heart disease ATTR-CM needs at least a 96% discount off its list price to be considered cost-effective under common benchmarks, a draft report by ICER has found.
STAT
JULY 29, 2024
New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported Sunday – but some appear to work far better than others. It’s tricky to tell if memory problems are caused by Alzheimer’s. That requires confirming one of the disease’s hallmark signs — buildup of a sticky protein called beta-amyloid — with a hard-to-get brain scan or uncomfortable spinal tap.
Fierce Healthcare
JULY 31, 2024
Humana affirmed its guidance for the year as it continues to face headwinds in the Medicare Advantage (MA) space. | Humana affirmed its guidance for the year as it continues to face headwinds in the Medicare Advantage space.
Pharmaceutical Technology
JULY 1, 2024
On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.
Pharmacy Times
JULY 18, 2024
The authors emphasize that clinical research should focus on real-world difficulties, and pediatric asthma control should be seen as a health care priority.
Drug Topics
JULY 1, 2024
Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.
Fierce Pharma
JULY 11, 2024
Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their attention to another facet of drug pricing with a bill meant to cr | The bill looks to limit the number of patents that companies can assert in litigation on individual products. It's intended to crack down on "patent thickets," which can delay and thwart generic competition.
STAT
JULY 29, 2024
Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company’s recently approved gene therapy for Duchenne muscular dystrophy, STAT has learned. The incident raises questions about the financial ties between Sarepta and the advocacy group, Parent Project Muscular Dystrophy, and whether the drugmaker uses its money to influence, or even muzzle, debate over its Duchenne medicines.
Expert insights. Personalized for you.
139 
Let's personalize your content